加味香苏饮加减治疗功能性消化不良上腹痛综合征（肝胃气滞型）的临床观察

发布时间：2018-05-06 00:07

本文选题：功能性消化不良 + 上腹痛综合征　；参考：《成都中医药大学》2016年硕士论文

【摘要】：目的：本研究通过与对照组相比较,探讨加味香苏饮加减治疗功能性消化不良上腹痛综合征(肝胃气滞型)的临床疗效和安全性。方法：将符合功能性消化不良上腹痛综合征(肝胃气滞型)诊断标准的40例患者随机分为对照组和治疗组各20例。对照组予枸橼酸莫沙必利分散片联合奥美拉唑肠溶胶囊治疗,治疗组予加味香苏饮加减治疗,疗程均为4周。通过对两组患者治疗前后的症状变化及停药1月后复发情况进行观察与记录,并采用SPSS19.0软件对治疗前后症状积分、近期疗效和复发率等方面进行统计分析,得出结论。结果：(1)近期疗效：治疗组、对照组的总有效率分别为85%、75%,两组比较有统计学意义(P0.05),治疗组的近期疗效优于对照组。(2)症状改善比较：两组均能有效的改善患者的临床症状,治疗组改善患者症状的疗效整体优于对照组(P0.05),特别是在改善患者胸胁胀满、呃逆、情绪抑郁或烦躁易怒、善太息等4个症状上面疗效优于对照组(P0.05),在改善患者胃脘胀痛、暖气、胃纳减少、上腹灼热、泛酸等5个症状上面疗效与对照组相似(P0.05)；而对照组在改善患者胸胁胀满、呃逆、情绪抑郁或急躁易怒、善太息等4个症状上无明显疗效(P0.05)。(3)安全性：两组患者在整个治疗疗程中未见不良反应。(4)复发情况：治疗结束后随访1个月,治疗组和对照组中分别有2、7例复发,复发率分别为11.8%、46.7%,两组比较有统计学意义(P0.05),治疗组的疗效比对照组的疗效更稳定。结论：“加味香苏饮”在改善功能性消化不良上腹痛综合征(肝胃气滞型)患者的临床症状、调节情绪上面有明显优势,且疗效稳定,具有较好的临床应用价值,值得临床推广与进一步研究。
[Abstract]:Objective: to investigate the clinical efficacy and safety of modified Xiangsuyin in the treatment of functional dyspepsia upper abdominal pain syndrome (liver-stomach qi stagnation) by comparing with control group. Methods: 40 patients with functional dyspepsia epigastric pain syndrome (liver-stomach qi stagnation) were randomly divided into two groups: control group (n = 20) and treatment group (n = 20). The control group was treated with mosapride citrate dispersible tablets combined with omeprazole enteric-coated capsule, and the treatment group was treated with modified Xiangsuyin for 4 weeks. By observing and recording the changes of symptoms before and after treatment and the recurrence after one month's withdrawal, the symptoms integral, short-term curative effect and recurrence rate before and after treatment were analyzed by SPSS19.0 software, and the conclusion was drawn. Results the short-term curative effect: the total effective rate of the treatment group and the control group was 8575, respectively. There was significant difference between the two groups (P 0.05). The short-term curative effect of the treatment group was better than that of the control group, and the symptom improvement comparison: both groups could effectively improve the clinical symptoms of the patients. The curative effect of the treatment group on improving the symptoms of the patients was better than that of the control group on the whole (P 0.05), especially in improving the patients' chest and hypochondriasis, hiccup, depression or irritability, easy to rest, etc., the curative effect of the treatment group was better than that of the control group (P 0.05), which was better than that of the control group in improving the patients' stomachache and heatiness. The effects of 5 symptoms, such as reduced stomach, upper abdominal burning and pantothenic acid, were similar to those of the control group (P 0.05), while the control group was able to improve the patients' chest and hypochondria fullness, hiccup, depression or irritability. There was no significant curative effect on 4 symptoms, such as Santaoxixi (P0.05). 3) Safety: there were no adverse reactions in the two groups during the whole course of treatment. The recurrence rate was: 1 month after treatment, 2 cases recurred in the treatment group and 7 cases in the control group, respectively, after the end of the treatment, there were 2 cases of recurrence in the treatment group and the control group, respectively. The recurrence rate was 11.8% and 46.7% respectively. There was significant difference between the two groups (P 0.05). The curative effect of the treatment group was more stable than that of the control group. Conclusion: "Jiawei Xiangsuyin" has obvious advantages in improving the clinical symptoms of patients with functional dyspepsia upper abdominal pain syndrome (liver-stomach qi stagnation type), and has obvious advantages in regulating emotion, and has a stable curative effect, which has good clinical application value. It is worthy of clinical popularization and further study.
【学位授予单位】：成都中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】